Approval of Un-audited Financial Results(Standalone and consolidated) Financial Results for the quarter ended 30th June, 2025
MANGALAM · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
On the reaction day the stock moved 4.8 pts less than Nifty Microcap 250 and 4.9 pts less than its Pharmaceuticals peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.
Minute windows have no benchmark: there is no intraday index history to compare against.
Mangalam Drugs and Organics Limited reported weak Q1 FY26 results. Total income from operations fell to Rs 5,734.87 lakhs, down about 25% from Rs 7,653.62 lakhs in the same quarter last year. The company swung from a net profit of Rs 268.47 lakhs in Q1 FY25 to a net loss of Rs 1,372.80 lakhs, resulting in a loss per share of Rs 8.67. Operating profit also turned negative at a loss of Rs 888.39 lakhs, compared to a profit of Rs 432.79 lakhs a year ago. The statutory auditor, V.S. Somani & Co., issued a clean limited review report with no modified opinion on both standalone and consolidated results. The filing also notes a pending merger scheme awaiting NCLT approval, with the creditors and shareholders meeting scheduled for August 12, 2025.
The sharp year-on-year revenue decline and steep swing into a sizeable quarterly loss are clearly negative for shareholders and could weigh on the stock in the near term. Investors should also watch the outcome of the NCLT-convened meeting on August 12, 2025 for the proposed merger, which could be a material catalyst.